logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
ABEO
Abeona Therapeutics Inc.
6.05
2 x 4.59
2 x 7.89
bid
ask
-
0.13
2.10%
2 @ 07:08 AM
6.06 +0.01 (0.17%)
Ytd14.80%
1y8.62%
6.04
day range
6.39
4.00
52 week range
7.54
Open6.17Prev Close6.18Low6.04High6.39Mkt Cap344.82M
Vol2.06MAvg Vol1.15MEPS0.95P/E6.37Forward P/E-3.84
Beta1.50Short Ratio10.79Inst. Own77.54%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1350-d Avg5.61200-d Avg5.201yr Est16.75

ABEO News

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w

Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
benzinga.com
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript

Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
benzinga.com
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network

Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market

benzinga.com
Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the anal

Earnings Scheduled For May 13, 2026
benzinga.com
Earnings Scheduled For May 13, 2026
benzinga.com
Abeona Therapeutics Activates Children's Hospital Of Philadelphia As Sixth Qualified Treatment Cente

Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing gene
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
benzinga.com
Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.34) per share which beat the anal

Earnings Scheduled For March 17, 2026
benzinga.com
Earnings Scheduled For March 17, 2026
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the anal

Earnings Scheduled For November 12, 2025
benzinga.com
Earnings Scheduled For November 12, 2025

What to Expect from Abeona Therapeutics's Earnings
benzinga.com
What to Expect from Abeona Therapeutics's Earnings
benzinga.com
Abeona Secures Permanent CMS J-Code J3389 For ZEVASKYN Gene Therapy In Recessive Dystrophic Epidermo

Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell
benzinga.com
Abeona Therapeutics Announced That Its ABO-503 Gene Therapy For X-linked Retinoschisis Has Been Sele

ABO-503 is composed of a functional human RS1 gene packaged in the novel AIM™ capsid AAV204. ABO-503
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
benzinga.com
Oppenheimer Maintains Outperform on Abeona Therapeutics, Raises Price Target to $20

Oppenheimer analyst Andreas Argyrides maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperfo
benzinga.com
Abeona Therapeutics Q2 EPS $1.71 Beats $(0.39) Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly earnings of $1.71 per share which beat the anal
benzinga.com
AscellaHealth Partnership With Abeona Therapeutics Highlights The Launch Commercialization Of ZEVAS

BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizab
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
benzinga.com
Bio-Techne's Simple Western Technology Utilized In FDA Approval Of ZEVASKYN, Developed By Abeona The

Bio-Techne Corporation (NASDAQ:TECH) today announced that its Simple Western™ Technology played a ke
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
benzinga.com
Abeona Therapeutics Nets $155M From Voucher Sale

Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the closing of the sale of its Rare Pediatric
benzinga.com
Abeona Therapeutics Announces It Has Exercised Its Option To License Abeona's Patented Aav204 Capsid

Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that Beacon Therapeutics, an ophthalmic gene

benzinga.com
Abeona Announces Publication Of Phase 3 VIITAL Study In The Lancet Highlighting ZEVASKYN's Impact On

RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds th
benzinga.com
Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19

Oppenheimer analyst Andreas Argyrides assumes Abeona Therapeutics (NASDAQ:ABEO) with a Outperform

PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's

Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
benzinga.com
Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20

Stifel analyst Dae Gon Ha maintains Abeona Therapeutics (NASDAQ:ABEO) with a Buy and lowers the p

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
benzinga.com
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast a

Abeona Stock Surges to 52-Week High: What's Behind The Move?
benzinga.com
Abeona Stock Surges to 52-Week High: What's Behind The Move?

Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Raises Price Target to $20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Abeona Therapeutics (NASDAQ:ABEO) wi

Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy
benzinga.com
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy

FDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in p
benzinga.com
The FDA Approves Abeona Therapeutics' Zevaskyn (Prademagene Zamikeracel) Gene-modified Cellular Shee

ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition

benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Abeona Therapeutics (NASDAQ:ABEO) with

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
benzinga.com
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wedne
benzinga.com
Oppenheimer Initiates Coverage On Abeona Therapeutics with Outperform Rating, Announces Price Target

Oppenheimer analyst Francois Brisebois initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) wi
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Abeona Therapeutics (NASDAQ:ABEO) with
benzinga.com
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
benzinga.com
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
benzinga.com
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
benzinga.com
Calix Reports Mixed Results, Joins Cadence Design Systems And Other Big Stocks Moving Lower In Tuesd
benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 807 companies reached new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 1043 companies hit new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  During Wednesday's trading, 435 companies set new 52-week lows.